GLP-1 agonists and amylin analogs show potential as adjunct therapies for type 1 diabetes in children, improving glycemic control and potentially reducing insulin requirements alongside standard insulin therapy.
Key findingGLP-1 agonists and amylin analogs show potential as adjunct therapies for type 1 diabetes in children, improving glycemic control and potentially redu
What the researchers found
GLP-1 agonists and amylin analogs show potential as adjunct therapies for type 1 diabetes in children, improving glycemic control and potentially reducing insulin requirements alongside standard insulin therapy.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
New potential adjuncts to treatment of children with type 1 diabetes mellitus.
Pediatric research, 65(4), 370-4
Citation
Raman, Vandana S; Heptulla, Rubina A. (2009). New potential adjuncts to treatment of children with type 1 diabetes mellitus.. Pediatric research, 65(4), 370-4. https://doi.org/10.1203/PDR.0b013e3181975ee4